Lv1
6 积分 2023-11-13 加入
Imlunestrant with or without Abemaciclib in Advanced Breast Cancer
1个月前
已完结
Key decision factors in second-line therapy: Expert insights on HR+/HER2-metastatic breast cancer post-CDK4/6 inhibitor progression
1个月前
已完结
Biliary Tract Cancers
2个月前
已完结
Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
6个月前
已完结
Final results of the double-blind placebo-controlled randomized phase 2 LOTUS trial of first-line ipatasertib plus paclitaxel for inoperable locally advanced/metastatic triple-negative breast cancer
6个月前
已完结
Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review
7个月前
已完结
皖公网安备34019202002308
